Corrections to Chiral Dynamics of Heavy Hadrons: (I) 1/M Correction

In earlier publications we have analyzed the strong and radiative decays of heavy hadrons in a formalism which incorporates both heavy-quark and chiral symmetries. In particular, we have derived a heavy-hadron chiral Lagrangian whose coupling constants are related by the heavy-quark flavor-spin symmetry arising from the QCD Lagrangian with infinitely massive quarks. In this paper, we re-examine the structure of the above chiral Lagrangian by including the effects of $1/m_Q$ corrections in the heavy quark effective theory. The relations among the coupling constants, originally derived in the heavy-quark limit, are modified by heavy quark symmetry breaking interactions in QCD. Some of the implications are discussed.Comment: PHYZZX, 45 pages, 1 figure (not included), CLNS 93/1192, IP-ASTP-02-93, ITP-SB-93-0

Probing flavor changing interactions in photon-photon collisions

We examine the subprocess $\gamma\gamma \to t\bar{c}+\bar{t}c$ at electron-positron colliders in the two-Higgs-doublet model with flavor-changing scalar couplings, where all the one-loop contribuions are considered, and the results are applicable to the whole mass range of the weakly coupled Higgs bosons. Because of the heavy top quark mass, this process is important in probing the flavor-changing top-charm-scalar vertex and could be detectable at the Next Linear Collider, if the values of the parameters are favorable. The results show that this process is more promising than the direct $e^{+} e^{-}$ process for discovering flavor changing scalar interactions.Comment: 22 pages, LaTeX, including 5 figures in eps file

Top-Charm Associated Production in High Energy e+e−e^+e^- Collisions

The possibility of exploring the flavor changing neutral current $tcZ/tc\gamma$ couplings in the production vertex for the reaction \epem\to t\bar c + \bar tc is examined. Using a model independent parameterization for the effective Lagrangian to describe the most general three-point interactions, production cross sections are found to be relatively small at LEP II, but potentially sizeable at higher energy \epem colliders. The kinematic characteristics of the signal are studied and a set of cuts are devised for clean separation of the signal from background. The resulting sensitivity to anomalous flavor changing couplings at LEP II with an integrated luminosity of $4\times 500$ pb$^{-1}$ is found to be comparable to their present indirect constraints from loop processes, while at higher energy colliders with $0.5-1$ TeV center-of-mass energy and 50-200 fb$^{-1}$ luminosity, one expects to reach a sensitivity at or below the percentage level.Comment: Latex, 22 page

Resumming the color-octet contribution to e+ e- -> J/psi + X

Recent observations of the spectrum of J/psi produced in e+ e- collisions at the Upsilon(4S) resonance are in conflict with fixed-order calculations using the Non-Relativistic QCD (NRQCD) effective field theory. One problem is that leading order color-octet mechanisms predict an enhancement of the cross section for J/psi with maximal energy that is not observed in the data. However, in this region of phase space large perturbative corrections (Sudakov logarithms) as well as enhanced nonperturbative effects are important. In this paper we use the newly developed Soft-Collinear Effective Theory (SCET) to systematically include these effects. We find that these corrections significantly broaden the color-octet contribution to the J/psi spectrum. Our calculation employs a one-stage renormalization group evolution rather than the two-stage evolution used in previous SCET calculations. We give a simple argument for why the two methods yield identical results to lowest order in the SCET power counting.Comment: 27 pages, 7 figure

B Physics at the Tevatron: Run II and Beyond

This report provides a comprehensive overview of the prospects for B physics at the Tevatron. The work was carried out during a series of workshops starting in September 1999. There were four working groups: 1) CP Violation, 2) Rare and Semileptonic Decays, 3) Mixing and Lifetimes, 4) Production, Fragmentation and Spectroscopy. The report also includes introductory chapters on theoretical and experimental tools emphasizing aspects of B physics specific to hadron colliders, as well as overviews of the CDF, D0, and BTeV detectors, and a Summary.Comment: 583 pages. Further information on the workshops, including transparencies, can be found at the workshop's homepage: http://www-theory.lbl.gov/Brun2/. The report is also available in 2-up http://www-theory.lbl.gov/Brun2/report/report2.ps.gz or chapter-by-chapter http://www-theory.lbl.gov/Brun2/report

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

BACKGROUND: Recombinant human erythropoietin (EPO) is used for the treatment of last stage renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of two recombinant EPO formulations in patients with anemia due to end-stage renal disease on hemodialysis. METHODS: A parallel, randomized, double blind study was performed. A single 100 IU/Kg EPO dose was administered subcutaneously. Heberitro (Heber Biotec, Havana, formulation A), a newly developed product and Eprex (CILAG AG, Switzerland, formulation B), as reference treatment were compared. Thirty-four patients with anemia due to end-stage renal disease on hemodialysis were included. Patients had not received EPO previously. Serum EPO level was measured by enzyme immunoassay (EIA) during 120 hours after administration. Clinical and laboratory variables were determined as pharmacodynamic and safety criteria until 216 hours. RESULTS: Both groups of patients were similar regarding all demographic and baseline characteristics. EPO kinetics profiles were similar for both formulations; the pharmacokinetic parameters were very close (i.e., AUC: 4667 vs. 4918 mIU.h/mL; Cmax: 119.1 vs. 119.7 mIU/mL; Tmax: 13.9 vs. 18.1 h; half-life, 20.0 vs. 22.5 h for formulations A and B, respectively). The 90% confidence intervals for the ratio between both products regarding these metrics were close to the 0.8 – 1.25 range, considered necessary for bioequivalence. Differences did not reach 20% in any case and were not determined by a formulation effect, but probably by a patients' variability effect. Concerning pharmacodynamic features, a high similitude in reticulocyte counts increments until 216 hours and the percentage decrease in serum iron until 120 hours was observed. There were no differences between formulations regarding the adverse events and their intensity. The more frequent events were pain at injection site (35.3%) and hypertension (29%). Additionally, further treatment of the patients with the study product yielded satisfactory increases in hemoglobin and hematocrit values. CONCLUSION: The formulations are comparable. The newly developed product should be acceptable for long-term application